Is the Y90-Radioembolization treatment effective on the intermediate-advanced stage of Hepatocellular Carcinoma and What is the Albumin-Bilirubin score's prediction factor for survival?
Authors:
- Sami EvirgenSESami Evirgen
- Bilger CavusBCBilger Cavus
- Suut GokturkSGSuut Gokturk
- Raim IliazRIRaim Iliaz
- Zeynep Gozde OzkanZOZeynep Gozde Ozkan
- Bulent BaranBBBulent Baran
- Aslı Ciftcibası OrmeciAOAslı Ciftcibası Ormeci
- Ozlem Mutluay SoyerOSOzlem Mutluay Soyer
- Cetin KaracaCKCetin Karaca
- Kadir DemirKDKadir Demir
- Selman Fatih BesisikSBSelman Fatih Besisik
- Arzu PoyanliAPArzu Poyanli
Open Access
- 1 January 2023
- journal article
- research article
- Published by Kare Publishing in Hepatology Forum
- Vol. 4 (3) , 103-107
Abstract
Background and Aim: Radioembolization (RE) is a one of the palliative treatments that have been used to down stage and/or increase the survival time in intermediate-advanced stages of HCC. We aimed to evaluate the clinical impact of RE and the clinical use of the albumin-bilirubin (ALBI) score as a predictor for survival in HCC patients. Materials and Methods: Fifty-nine unresectable hepatocellular carcinoma (HCC) patients were enrolled. RE was performed in 28 of them (group 1) and 31 patients were followed up in the natural course (NC) (group 2). Patients were classified according to the Child-Pugh score (only cirrhotic patients), Barcelona clinic liver cancer (BCLC) staging, and ALBI scores were also calculated. Results: All patients in Group 1 were cirrhotic and their BCLC stages were as follows: 60.7% stage B and 39.3% stage C. In Group 2, 83.9% of patients were cirrhotic and their BCLC stages were as follows: 9.7% stage B, 51.6% stage C, and 38.7% stage D. Mortality rates were 82% and 100% in Groups 1 and 2, respectively. The median overall survival (OS) was 13.5 months (95% CI: 10.4–16.6 months) and 4.5 months (95% CI: 3.5–5.5 months) in Groups 1 and 2, respectively (p=0.000). When RE was applied to patients with ALBI Grade 1 and 2, the median OS was statistically higher than in the NC group, respectively (pKeywords
This publication has 26 references indexed in Scilit:
- Downstaging Hepatocellular Carcinoma with Yttrium-90 radioembolization: Resection or transplantation?European Journal of Surgical Oncology, 2014
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trialJournal of Hepatology, 2012
- Survival after Yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluationHepatology, 2011
- Radioembolization Results in Longer Time-to-Progression and Reduced Toxicity Compared With Chemoembolization in Patients With Hepatocellular CarcinomaGastroenterology, 2011
- Radioembolization with Yttrium-90 Glass Microspheres in Hepatocellular Carcinoma: European Experience on Safety and Long-Term SurvivalHepatology, 2010
- A Comparative Analysis of Transarterial Downstaging for Hepatocellular Carcinoma: Chemoembolization Versus RadioembolizationAmerican Journal of Transplantation, 2009
- Incidence of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C-Related Advanced Liver DiseaseGastroenterology, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Treatment of Unresectable Hepatocellular Carcinoma with Intrahepatic Yttrium 90 Microspheres: A Risk-Stratification AnalysisJournal of Vascular and Interventional Radiology, 2005
- Metastases in Cases with Hepatocellular Carcinoma in Relation to Clinicopathologic Features of the Tumour An autopsy study from a low endemic areaActa Oncologica, 1995